Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and iBio (NASDAQ:IBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.
Earnings & Valuation
This table compares Whitehawk Therapeutics and iBio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | $7.14 million | 33.46 | -$20.60 million | ($1.12) | -3.74 |
| iBio | $100,000.00 | 810.27 | -$33.04 million | ($0.34) | -3.71 |
Insider & Institutional Ownership
52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
Whitehawk Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Whitehawk Therapeutics and iBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| iBio | 1 | 0 | 4 | 3 | 3.12 |
Whitehawk Therapeutics currently has a consensus target price of $8.20, indicating a potential upside of 95.70%. iBio has a consensus target price of $5.00, indicating a potential upside of 296.83%. Given iBio’s stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Whitehawk Therapeutics.
Profitability
This table compares Whitehawk Therapeutics and iBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
| iBio | N/A | -40.66% | -35.78% |
Summary
iBio beats Whitehawk Therapeutics on 9 of the 14 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
